Xenofon Baraliakos Selected Research

Ankylosing Spondylitis

11/2022	Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
7/2022	Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
6/2022	Instrument selection for the ASAS core outcome set for axial spondyloarthritis.
4/2022	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
1/2022	Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
1/2022	Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
1/2022	Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis.
1/2022	Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
1/2022	Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
12/2021	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xenofon Baraliakos Research Topics

Disease

76	Ankylosing Spondylitis 11/2022 - 01/2004
46	Axial Spondyloarthritis 11/2022 - 10/2012
26	Inflammation (Inflammations) 11/2022 - 10/2008
16	Necrosis 11/2022 - 07/2009
16	Psoriatic Arthritis 04/2022 - 01/2004
14	Pain (Aches) 04/2022 - 11/2006
12	Rheumatoid Arthritis 11/2022 - 09/2014
10	Non-Radiographic Axial Spondyloarthritis 04/2022 - 09/2012
10	Back Pain (Backache) 04/2022 - 01/2004
9	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2022 - 07/2009
6	Arthritis (Polyarthritis) 11/2022 - 03/2009
6	Ankylosis 01/2022 - 01/2004
4	Uveitis 06/2022 - 03/2009
4	Infections 01/2021 - 03/2007
3	Synovitis 01/2022 - 11/2016
3	COVID-19 01/2022 - 07/2021
3	Rheumatic Diseases (Rheumatism) 01/2021 - 01/2017
3	Sacroiliitis 03/2020 - 03/2009
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2022 - 01/2010
2	Sclerosis 01/2022 - 06/2018
2	Fatigue 01/2020 - 09/2019
2	Intervertebral Disc Degeneration 01/2019 - 01/2004
2	Spinal Stenosis (Stenosis, Spinal) 01/2019 - 07/2010
2	Crohn Disease (Crohn's Disease) 12/2015 - 03/2015
1	Neoplasms (Cancer) 11/2022
1	Bone Resorption 11/2022
1	Venous Thromboembolism 11/2022
1	Osteoarthritis 11/2022
1	Connective Tissue Diseases (Connective Tissue Disease) 11/2022
1	Spondylitis 04/2022
1	Enthesopathy 01/2022
1	Premature Birth (Birth, Premature) 01/2022
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 01/2022
1	Gout 01/2022
1	Joint Diseases (Joint Disease) 01/2022
1	Lordosis 01/2022
1	Metaplasia 01/2022
1	Musculoskeletal Diseases (Musculoskeletal Disease) 10/2021
1	Nociceptive Pain 04/2021

Drug/Important Bio-Agent (IBA)

22	secukinumabIBA 04/2022 - 11/2013
21	Biological ProductsIBA 11/2022 - 12/2010
16	C-Reactive ProteinIBA 11/2022 - 03/2009
16	Antirheumatic Agents (DMARD)IBA 11/2022 - 01/2017
14	Tumor Necrosis Factor InhibitorsIBA 11/2022 - 01/2010
13	Infliximab (Remicade)FDA Link 01/2022 - 01/2005
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2004
11	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2022 - 09/2006
10	Interleukin-17 (Interleukin 17)IBA 11/2022 - 11/2013
9	Monoclonal AntibodiesIBA 12/2021 - 11/2013
8	ixekizumabIBA 11/2022 - 12/2018
8	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 11/2006
8	golimumab FDA Link 01/2020 - 12/2011
7	GlucocorticoidsIBA 10/2022 - 09/2014
7	Etanercept (Enbrel)FDA Link 04/2022 - 12/2011
6	Adalimumab (Humira)FDA Link 11/2022 - 12/2011
6	AntibodiesIBA 07/2022 - 03/2007
6	Certolizumab Pegol FDA Link 01/2022 - 01/2017
5	InterleukinsIBA 04/2022 - 01/2020
5	Biosimilar PharmaceuticalsIBA 11/2021 - 03/2015
4	Immunoglobulin A (IgA)IBA 07/2022 - 01/2019
4	Biomarkers (Surrogate Marker)IBA 07/2022 - 12/2011
4	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 04/2022 - 12/2011
4	GLPG0634IBA 01/2022 - 12/2018
4	AutoantibodiesIBA 01/2021 - 01/2019
3	upadacitinibIBA 11/2022 - 01/2022
3	Methotrexate (Mexate)FDA LinkGeneric 10/2022 - 07/2009
3	Prednisolone (Predate)FDA LinkGeneric 10/2022 - 09/2014
3	CytokinesIBA 01/2021 - 11/2013
3	Immunoglobulin G (IgG)IBA 01/2021 - 01/2019
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 04/2019
2	Dopamine Receptors (Dopamine Receptor)IBA 11/2022 - 01/2022
2	Janus Kinase InhibitorsIBA 11/2022 - 01/2021
2	bimekizumabIBA 07/2022 - 01/2020
2	Analgesics (Analgesic Drugs)IBA 01/2022 - 06/2017
2	propylene diquat (PDQ(+))IBA 04/2021 - 07/2017
2	AntigensIBA 01/2021 - 05/2020
2	tofacitinibIBA 01/2021 - 01/2018
2	Interleukin-12 (IL 12)IBA 01/2020 - 03/2015
2	Pharmaceutical PreparationsIBA 12/2018 - 11/2006
2	FluoridesIBA 06/2018 - 09/2015
1	Tolonium Chloride FDA Link 11/2022
1	calinIBA 04/2022
1	rhenium sulfide (ReS2)IBA 01/2022
1	CT-P13IBA 01/2022
1	FluorineIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	SteroidsIBA 01/2022
1	N 30IBA 01/2022
1	Interleukin-23 (Interleukin 23)IBA 12/2021
1	RA 25IBA 11/2021
1	VaccinesIBA 10/2021

Therapy/Procedure

35	Therapeutics 11/2022 - 01/2004
7	Biological Therapy 11/2022 - 07/2013
3	Drug Tapering 03/2021 - 01/2020
2	Injections 01/2020 - 12/2016
2	Physical Therapy Modalities (Physical Therapy Technique) 07/2017 - 08/2012
1	Radiotherapy 01/2022
1	Drug Therapy (Chemotherapy) 01/2022
1	Cesarean Section (Caesarean Section) 01/2022
1	Immunomodulation 07/2021